IR-Med (IRME) Liabilities and Shareholders Equity (2020 - 2025)

IR-Med's Liabilities and Shareholders Equity history runs 6 years deep, the most recent figure standing at $175000.0 for Q2 2025.

• In Q2 2025, Liabilities and Shareholders Equity fell 80.27% year-over-year to $175000.0; the TTM figure through Jun 2025 stood at $1.1 million (down 74.45% YoY), while the FY2024 annual figure was $251000.0, down 74.87% from the prior year.
• Liabilities and Shareholders Equity came in at $175000.0 for Q2 2025 at IR-Med, up from $124000.0 in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $4.5 million in Q2 2022 to a low of $124000.0 in Q1 2025.
• A 5-year average of $2.0 million and a median of $2.1 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity soared 40.81% in 2021 and tumbled 80.27% in 2025, its largest moves.
• IR-Med's Liabilities and Shareholders Equity stood at $2.9 million in 2021, then grew by 11.93% to $3.3 million in 2022, then sank by 69.67% to $999000.0 in 2023, then sank by 74.87% to $251000.0 in 2024, then tumbled by 30.28% to $175000.0 in 2025.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $175000.0, $124000.0, and $251000.0 for Q2 2025, Q1 2025, and Q4 2024 respectively.

Peer Comparison